Ahmad A. Tarhini, MD, PhD (IMAGE)

ECOG-ACRIN Cancer Research Group

Ahmad A. Tarhini, MD, PhD

Caption

“The new survival prediction methods leverage low-cost, easily accessible technologies. They have the potential to speed up TLS testing adoption for high-risk melanoma patients, which could in turn aid discussions between physicians and patients on potential immunotherapy benefits,” said Ahmad A. Tarhini, MD, PhD, professor and senior member, cutaneous oncology and immunology, at the Moffitt Cancer Center and Research Institute in Tampa, Florida

Credit

Moffitt Cancer Center and Research Institute

Usage Restrictions

No restrictions.

License

Public Domain

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.